Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2005

01-04-2005 | Original Article

Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma

Authors: Jan A. Boucek, J. Harvey Turner

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2005

Login to get access

Abstract

Purpose

Radioimmunotherapy (RIT) for relapsed non-Hodgkin’s lymphoma is emerging as a promising treatment strategy. Myelosuppression is the dose-limiting toxicity and may be particularly problematic in patients heavily pretreated with chemotherapy. Reliable dosimetry is likely to minimise toxicity and improve treatment efficacy, and the aim of this study was to elucidate the complex problems of dosimetry of RIT by using an integrated SPECT/CT system.

Methods

As a part of a clinical trial of 131I-anti-CD20 rituximab RIT of non-Hodgkin’s lymphoma, we employed a patient-specific prospective dosimetry method utilising the whole-body effective half-life of antibody and the patient’s ideal weight to calculate the administered activity for RIT corresponding to a prescribed radiation absorbed dose of 0.75 Gy to the whole body. A novel technique of quantitation of bone marrow uptake with hybrid SPECT/CT imaging was developed to validate this methodology by using post-RIT extended imaging and data collection.

Results

A strong, statistically significant correlation (p=0.001) between whole-body effective half-life of antibody and effective marrow half-life was demonstrated. Furthermore, it was found that bone marrow activity concentration was proportional to administered activity per unit weight, height or body surface area (p<0.001).

Conclusion

The results of this study show the proposed whole-body dosimetry method to be valid and clinically applicable for safe, effective RIT.
Appendix
Available only for authorised users
Literature
1.
Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin’s lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003;18:513–24.CrossRefPubMed
2.
Wahl RL. Iodine-131 anti-B1 antibody therapy in non-Hodgkin’s lymphoma: dosimetry and clinical implications. J Nucl Med 1998;39(suppl):1S–9S.PubMed
3.
Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998;39(suppl):9S–16S.
4.
Wiseman GA, Leigh B, Lamonica D, Kornmehl E, Spies SM, Silverman DHS, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002;94:1349–57.PubMed
5.
DeNardo SJ, DeNardo GL, Kukis D, Shen S, Kroger L, DeNardo DA, et al. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumour regression in patients with lymphoma. J Nucl Med 1999;40:303–10
6.
Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay R, Hoffman R, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989;15:784–95.PubMed
7.
Rizzieri DA, Akabani G, Zalutsky M, Coleman RE, Metzler SD, Bowsher JE, et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 2004;104:642–8.CrossRefPubMed
8.
Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689–94.PubMed
9.
Macey DJ, DeNardo SJ, DeNardo GL, DeNardo DA, Shen S. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Clin Nucl Med 1995;20:117–25.PubMed
10.
Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538–46.PubMed
11.
Bouchet LG, Bolch WE, Howell RW, Rao DV. S values for radionuclides localized within the skeleton. J Nucl Med 2000;41:189–212.
12.
Bolch WE, Patton PW, Rajon DA, Shah AP, Jokisch DW, Inglis BA. Considerations of marrow cellularity in 3-dimensional dosimetric models of the trabecular skeleton. J Nucl Med 2002;43:97–108.PubMed
13.
Stabin MG, Eckerman KF, Bolch WE, Bouchet LG, Patton PW. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm 2002;17:427–33.CrossRefPubMed
14.
Coffey JL, Watson EE. Calculating dose from remaining body activity: a comparison of two methods. Med Phys 1979;6:307–8.CrossRefPubMed
15.
Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from four clinical trials. J Nucl Med 2003;44:465–74.PubMed
16.
Snyder WS et al. Report of the task group on reference man. Pergamon Press, ICRP report No.23. Oxford, UK: International Commission on Radiological Protection; 1974.
17.
Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma: from clinical trials to clinical practice. J Nucl Med 2002;43:1507–29.PubMed
18.
ICRP 70, Basic anatomical and physiological data for use in radiological protection: the skeleton. ICRP publication 70. Oxford, UK: International Commission on Radiological Protection; 1995.
19.
Patton JA, Delbeke D, Sandler MP. Image fusion using an integrated, dual-head coincidence camera with X-ray tube-based attenuation maps. J Nucl Med 2000;41:1364–68.
20.
Knoos T, Nilsson M, Ahlgren L. A method for conversion of Hounsfield number to electron density and prediction of macroscopic pair production cross-sections. Radiother Oncol 1986;5:337–45.PubMed
21.
Duck FA. Physical properties of tissue: a comprehensive reference book. New York: Academic Press; 1990.
Metadata
Title
Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma
Authors
Jan A. Boucek
J. Harvey Turner
Publication date
01-04-2005
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2005
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-004-1692-9

Other articles of this Issue 4/2005

European Journal of Nuclear Medicine and Molecular Imaging 4/2005 Go to the issue

Original Article

Survival benefit after revascularization is independent of left ventricular ejection fraction improvement in patients with previous myocardial infarction and viable myocardium

Editorial

Differences and similarities between coronary atherosclerosis and ischaemic heart disease: implications for cardiac imaging

Letter to the Editor

11C-methionine PET versus 99mTc-sestamibi in the pre-operative localisation of hyperfunctional parathyroid tissue

Image of the Month

Visualisation of impaired dopamine biosynthesis in a case of aromatic l-amino acid decarboxylase deficiency by co-registered 18F-FDOPA PET and magnetic resonance imaging

Original Article

Myocardial β-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[11C]CGP12388

Original Article

In vivo biodistribution and pharmacokinetics of 18F-labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals